About Us

Drug Discovery Initiative, DDI, has been founded to contribute to the health of people through elucidation of the phenomena of life or development of orphan drugs as a hub of the national collaborative research network for drug discovery based on our public chemical library. We promote open innovation by providing consultation, technical assistance and chemical samples to the researchers who will begin chemical screening.

Contact Us

Drug Discovery Initiative

The University of Tokyo

Pharmaceutical Sci. Main Building, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan

Telephone: +81-3-5841-1960

Facsimile: +81-3-5841-1959

E-mail: ddiinfomol.f.u-tokyo.ac.jp

Member

Director, Hidenori Ichijo, D.D.S., Ph.D.
Deputy Director, Hirotatsu Kojima, Ph.D
Professor, Yuichi Hashimoto, Ph. D.
Professor, Hiroyuki Miyachi, Ph.D.
Professor, Takayoshi Okabe, Ph.D.
Professor, Kohei Tsumoto, Ph.D.
Associate Professor, Hidenori Azami, Ph.D.
Associate Professor, Naoki Suto, Ph.D.
Lecturer, Tomoaki Kawano, Ph.D.
Lecturer, Hirofumi Nakano, Ph.D.
Lecturer, Masao Sakairi, Ph.D.
Lecturer, Masanori Suzuki, Ph.D.
Assistant Professor, Satoru Nagatoishi, Ph.D.
Member, Tomoko Futamata
Member, Tsukasa Hasegawa, M.S.
Member, Emi Hayashida, M.S.
Member, Chinatsu Honma, M.S.
Member, Yousuke Ikeda, M.S.
Member, Riyo Imamura, M.S.
Member, Yoshiko Inoue
Member, Mayumi Ishii
Member, Satoshi Kitamura, Ph.D.
Member, Chie Koda
Member, Izumi Minegishi
Member, Nae Saito, M.S.
Technical Specialist, Kiyoe Hayashi
Visiting / Emeritus Professor, Tetsuo Nagano, Ph.D.
Visiting Associate Professor, Kazuo Kumagai, Ph.D.

Management Committee

Hidenori Ichijo, D.D.S., Ph.D.

Hiroyuki Arai, Ph.D.

Yuichi Hashimoto, Ph.D.

Takeshi Iwatsubo, M.D., Ph.D.

Hirotatsu Kojima, Ph.D.

Hiroyuki Miyachi, Ph.D.

Takayoshi Okabe, Ph.D.

Kohei Tsumoto, Ph.D.

Advisory Board

Kazuo Hotate, Ph.D.

Hidenori Ichijo, D.D.S., Ph.D.

Kohei Miyazono, M.D., Ph.D.

Our Mission

Human genome analysis makes a great impact on the field of life sciences. The impact extends to organic synthetic chemistry and the phenomenon that was discussed at the clinical level previously has came to be discussed at the level of basic medicine, molecular biology and moreover the molecule including organic chemistry. The integrated research of organic chemistry, biology and medicine is demanded.

The development of a useful “synthetic small molecular compound regulating a biological function” has possibility to be equal to RNAi or knockout animal technology which is innovative in life science study, and could provide useful research tools. As the study of organic chemistry has developed highly now, design and synthesis of the organic compound in a logical, rational way is expected to come true. “The field of study to elucidate biological system with chemical techniques” is called Chemical Biology and actively performed these days mainly in the USA as a new field.

A public chemical library is the important study base for the development of “synthetic small molecular compound regulating a biological function”. By construction of the chemical library, it will be possible to find “a hit compound” regulating a biological function from more than 100,000 compounds in a short time. And then an optimization study to give selectivity and high potency to “a hit compound” comes to be performed, which is possible for the first time by making full use of the state of the art organic chemistry with structure analysis data of the protein and molecule design technology and will generate so-called “lead compound”. This “lead compound” is worth extremely high intellectual property.

The construction of the high quality chemical library is important in this process. However, there was not a public chemical library in Japan. On the other hand, organic synthetic chemistry research of Japanese Universities is at a high level worldwide, but most new synthetic compounds are hoarded up in university laboratories and not used enough as intellectual property.

Under such conditions, “Chemical Biology Research Initiative (CBRI)” was constructed in the University of Tokyo for the purpose of making use of intellectual properties of universities in industry and contributing to life science study. For the construction of CBRI, collaboration among study groups of organic synthetic chemistry is necessary and furthermore the support of life science laboratories is demanded for evaluating chemical library. CBRI collected compounds in the original way and build a storage/supply system. On April 1, 2011, the name of the organization was changed to “Open Innovation Center for Drug Discovery (OCDD)” in order to effectively connect universities’ intellectual property with industry. On April 1, 2015, the name of the organization was changed to “Drug Discovery Initiative (DDI).” DDI will support and accelerate academic drug discovery to contribute the Healthcare Policy of the Government.

As shown in the schematic diagram, “synthetic compound regulating a biological function” will be created efficiently by promoting collaboration among research groups of different fields such as organic synthetic chemistry, medical science, analytical chemistry, biophysics and life science. Furthermore, various research groups in the university are expected to join this collaboration. DDI aims to promote coordination within the university and active collaboration with research community inside and outside the country.

Chemical Library

Screening Systems

Infrastructure

Providing Samples

Our Network

Target Proteins Research Program Leading-edge Research Infrastructure Program Platform for Drug Discovery, Informatics, and Structure Life Sciences